vTv Therapeutics Sets Oct. 20 KOL Event on Type 1 Diabetes Drug
vTv Therapeutics will host a virtual KOL event Oct. 20 to discuss cadisegliatin, its oral Type 1 diabetes candidate, and the Phase 3 program.
vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company based in High Point, N.C., announced Tuesday it will convene a virtual key opinion leader event on October 20, 2026, at 2:30 PM ET to examine hypoglycemia in Type 1 diabetes and the development trajectory of its lead investigational compound, cadisegliatin.
Cadisegliatin is described by the company as a novel oral therapy targeting Type 1 diabetes, a condition in which patients typically rely on insulin and face persistent risks of dangerous blood-sugar swings. KOL events of this kind are typically used by clinical-stage companies to give investors and analysts direct access to medical experts who can assess a drug's scientific rationale and competitive positioning ahead of pivotal trial readouts.
Read more City National Bank Reopens Palisades Village Branch After LA Wildfires →
The announcement signals that vTv is preparing to raise the profile of its Phase 3 program for cadisegliatin at a time when oral alternatives to injectable insulin regimens remain a significant unmet need in the diabetes market. No additional details about featured speakers or agenda topics were disclosed in the company's announcement.
Registration for the virtual event is available through the company's investor relations channels. Investors and healthcare professionals interested in the Phase 3 timeline or clinical data are expected to have the opportunity to engage directly during the session.
Continue reading at GlobeNewswire - Industry News on Financial Services.
